Living with Limits: Device and Biotech Venture Capital
Executive Summary
Lacking exits from either IPOs or acquisitions, squeezing returns out of biotech and device start-ups has become an increasingly difficult game. Many generalist VC firms have fled to the far more lucrative business of Internet and IT investing, particularly since both health care and IT have become far more technologically complex. Thus specialists have been taking over a much greater percentage of health care dealmaking, though shunning most of the high-risk biotech and device investing of the 80s and 90s. Their investments begin with a clearly defined, and sometimes pre-arranged, exit.
You may also be interested in...
QUOTED. 10 April 2020. Shawn Patterson.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
New China Drug Regulation Legalizes Emergency Approval Mechanism
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Need a specific report? 1000+ reports available
Buy Reports